Literature DB >> 24128681

Kallikrein cascades in traumatic spinal cord injury: in vitro evidence for roles in axonopathy and neuron degeneration.

Maja Radulovic1, Hyesook Yoon, Nadya Larson, Jianmin Wu, Rachel Linbo, Joshua E Burda, Eleftherios P Diamandis, Sachiko I Blaber, Michael Blaber, Michael G Fehlings, Isobel A Scarisbrick.   

Abstract

Kallikreins (KLKs) are a family of 15 secreted serine proteases with emerging roles in neurologic diseases. To illuminate their contributions to the pathophysiology of spinal cord injury (SCI), we evaluated acute through chronic changes in the immunohistochemical appearance of 6 KLKs (KLK1, KLK5, KLK6, KLK7, KLK8, and KLK9) in postmortem human traumatic SCI cases, quantified their RNA expression levels in experimental murine SCI, and assessed the impact of recombinant forms of each enzyme toward murine cortical neurons in vitro. Temporally and spatially distinct changes in KLK expression were observed with partially overlapping patterns between human and murine SCI, including peak elevations (or reductions) during the acute and subacute periods. Kallikrein 9 showed the most marked changes and remained chronically elevated. Importantly, a subset of KLKs (KLK1, KLK5, KLK6, KLK7, and KLK9) were neurotoxic toward primary neurons in vitro. Kallikrein immunoreactivity was also observed in association with swollen axons and retraction bulbs in the human SCI cases examined. Together, these findings demonstrate that elevated levels of a significant subset of KLKs are positioned to contribute to neurodegenerative changes in cases of CNS trauma and disease and, therefore, represent new potential targets for the development of neuroprotective strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24128681      PMCID: PMC4097185          DOI: 10.1097/NEN.0000000000000007

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  94 in total

1.  Extracellular serine protease neuropsin (KLK8) modulates neurite outgrowth and fasciculation of mouse hippocampal neurons in culture.

Authors:  Takuya Oka; Morito Akisada; Akihito Okabe; Katsutoshi Sakurai; Sadao Shiosaka; Keiko Kato
Journal:  Neurosci Lett       Date:  2002-03-22       Impact factor: 3.046

2.  Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease.

Authors:  K Ogawa; T Yamada; Y Tsujioka; J Taguchi; M Takahashi; Y Tsuboi; Y Fujino; M Nakajima; T Yamamoto; H Akatsu; S Mitsui; N Yamaguchi
Journal:  Psychiatry Clin Neurosci       Date:  2000-08       Impact factor: 5.188

3.  Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain.

Authors:  S P Little; E P Dixon; F Norris; W Buckley; G W Becker; M Johnson; J R Dobbins; T Wyrick; J R Miller; W MacKellar; D Hepburn; J Corvalan; D McClure; X Liu; D Stephenson; J Clemens; E M Johnstone
Journal:  J Biol Chem       Date:  1997-10-03       Impact factor: 5.157

Review 4.  Update on the pathophysiology and pathology of acute spinal cord injury.

Authors:  C H Tator
Journal:  Brain Pathol       Date:  1995-10       Impact factor: 6.508

5.  Proteinase-activated receptors, targets for kallikrein signaling.

Authors:  Katerina Oikonomopoulou; Kristina K Hansen; Mahmoud Saifeddine; Illa Tea; Michael Blaber; Sachiko I Blaber; Isobel Scarisbrick; Patricia Andrade-Gordon; Graeme S Cottrell; Nigel W Bunnett; Eleftherios P Diamandis; Morley D Hollenberg
Journal:  J Biol Chem       Date:  2006-08-02       Impact factor: 5.157

6.  Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial.

Authors:  Reinhard von Wasielewski; Michael Mengel; Birgitt Wiese; Thomas Rüdiger; Hans Konrad Müller-Hermelink; Hans Kreipe
Journal:  Am J Clin Pathol       Date:  2002-11       Impact factor: 2.493

7.  Characterization of the early neuroinflammation after spinal cord injury in mice.

Authors:  Tiffany Rice; Jennifer Larsen; Serge Rivest; V Wee Yong
Journal:  J Neuropathol Exp Neurol       Date:  2007-03       Impact factor: 3.685

8.  Neuropsin regulates an early phase of schaffer-collateral long-term potentiation in the murine hippocampus.

Authors:  S Komai; T Matsuyama; K Matsumoto; K Kato; M Kobayashi; K Imamura; S Yoshida; S Ugawa; S Shiosaka
Journal:  Eur J Neurosci       Date:  2000-04       Impact factor: 3.386

9.  Kallikrein 6 regulates early CNS demyelination in a viral model of multiple sclerosis.

Authors:  Isobel A Scarisbrick; Hyesook Yoon; Michael Panos; Nadya Larson; Sachiko I Blaber; Michael Blaber; Moses Rodriguez
Journal:  Brain Pathol       Date:  2012-03-21       Impact factor: 6.508

10.  Kallikrein 6 signals through PAR1 and PAR2 to promote neuron injury and exacerbate glutamate neurotoxicity.

Authors:  Hyesook Yoon; Maja Radulovic; Jianmin Wu; Sachiko I Blaber; Michael Blaber; Michael G Fehlings; Isobel A Scarisbrick
Journal:  J Neurochem       Date:  2013-05-27       Impact factor: 5.372

View more
  18 in total

1.  Genetic targeting of protease activated receptor 2 reduces inflammatory astrogliosis and improves recovery of function after spinal cord injury.

Authors:  Maja Radulovic; Hyesook Yoon; Jianmin Wu; Karim Mustafa; Michael G Fehlings; Isobel A Scarisbrick
Journal:  Neurobiol Dis       Date:  2015-08-24       Impact factor: 5.996

2.  Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response.

Authors:  Michael Panos; George P Christophi; Moses Rodriguez; Isobel A Scarisbrick
Journal:  Biol Chem       Date:  2014-09       Impact factor: 3.915

3.  Protease activated receptor 2 controls myelin development, resiliency and repair.

Authors:  Hyesook Yoon; Maja Radulovic; Grant Walters; Alex R Paulsen; Kristen Drucker; Phillip Starski; Jianmin Wu; David P Fairlie; Isobel A Scarisbrick
Journal:  Glia       Date:  2017-09-18       Impact factor: 7.452

4.  Kallikrein-related peptidase 6 exacerbates disease in an autoimmune model of multiple sclerosis.

Authors:  Hyesook Yoon; Isobel A Scarisbrick
Journal:  Biol Chem       Date:  2016-12-01       Impact factor: 3.915

5.  Nafamostat mesilate attenuates inflammation and apoptosis and promotes locomotor recovery after spinal cord injury.

Authors:  Hui-Quan Duan; Qiu-Li Wu; Xue Yao; Bao-You Fan; Hong-Yu Shi; Chen-Xi Zhao; Yan Zhang; Bo Li; Chao Sun; Xiao-Hong Kong; Xin-Fu Zhou; Shi-Qing Feng
Journal:  CNS Neurosci Ther       Date:  2018-01-19       Impact factor: 5.243

Review 6.  Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms.

Authors:  Amaly Nokkari; Hadi Abou-El-Hassan; Yehia Mechref; Stefania Mondello; Mark S Kindy; Ayad A Jaffa; Firas Kobeissy
Journal:  Prog Neurobiol       Date:  2018-01-31       Impact factor: 11.685

7.  Blocking Kallikrein 6 promotes developmental myelination.

Authors:  Hyesook Yoon; Erin M Triplet; Whitney L Simon; Chan-Il Choi; Laurel S Kleppe; Elena De Vita; Aubry K Miller; Isobel A Scarisbrick
Journal:  Glia       Date:  2021-10-09       Impact factor: 7.452

Review 8.  Reactive gliosis and the multicellular response to CNS damage and disease.

Authors:  Joshua E Burda; Michael V Sofroniew
Journal:  Neuron       Date:  2014-01-22       Impact factor: 17.173

9.  Targeting the thrombin receptor modulates inflammation and astrogliosis to improve recovery after spinal cord injury.

Authors:  Maja Radulovic; Hyesook Yoon; Jianmin Wu; Karim Mustafa; Isobel A Scarisbrick
Journal:  Neurobiol Dis       Date:  2016-05-01       Impact factor: 5.996

10.  Kallikrein-related peptidase 6 orchestrates astrocyte form and function through proteinase activated receptor-dependent mechanisms.

Authors:  Hyesook Yoon; Maja Radulovic; Isobel A Scarisbrick
Journal:  Biol Chem       Date:  2018-09-25       Impact factor: 3.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.